MedAvail (MDVLQ) 10-Q 16 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 12, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	MYOS Corp
Entity Central Index Key	1,402,479
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		3,322,909

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash	$ 785	$ 1,567
Accounts receivable, net	615	982
Inventories, net	1,814	1,814
Prepaid expenses and other current assets	471	745
Total current assets	3,685	5,108
Fixed assets, net	301	313
Intangible assets, net	1,833	1,990
Total assets	5,819	7,411
Current liabilities:
Accounts payable	229	79
Accrued expenses and other current liabilities	574	495
Term note	300
Total current liabilities	1,103	574
Contract liability	114	101
Total liabilities	$ 1,217	$ 675
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.001 par value; 500,000 shares authorized; no shares issued and outstanding
Common stock, $.001 par value; 8,000,000 shares authorized; 3,317,909 and 3,103,300 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	$ 3	$ 3
Additional paid-in capital	26,746	25,100
Accumulated deficit	(22,147)	(18,367)
Total stockholders' equity	4,602	6,736
Total liabilities and stockholders' equity	$ 5,819	$ 7,411

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Balance Sheets [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	8,000,000	8,000,000
Common stock, shares issued	3,317,909	3,103,300
Common stock, shares outstanding	3,317,909	3,103,300

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Statements of Operations [Abstract]
Net revenues	$ 36	$ 107	$ 124	$ 3,332
Cost of sales (excludes amortization of acquired intangibles)	396	232	432	1,282
Gross profit	(360)	(125)	(308)	2,050
Operating expenses
Research and development	231	365	634	1,094
Selling, general and administrative	645	1,637	2,668	4,452
Amortization	$ 53	$ 50	$ 158	100
Loss on asset impairment				5
Total operating expenses	$ 929	$ 2,052	$ 3,460	5,651
Operating loss	(1,289)	$ (2,177)	(3,768)	(3,601)
Other income (expense):
Interest income	1		1	$ 2
Interest expense	(5)		(11)
Loss before income taxes	(1,293)	$ (2,177)	(3,778)	$ (3,599)
Income tax expense - current	(1)		(2)
Net loss and comprehensive loss	$ (1,294)	$ (2,177)	(3,780)	$ (3,599)
Deemed dividend resulting from warrant modification			(225)
Net loss attributable to common shareholders	$ (1,294)	$ (2,177)	$ (4,005)	$ (3,599)
Net loss per share attributable to common shareholders:
Basic and diluted	$ (0.39)	$ (0.75)	$ (1.25)	$ (1.28)
Weighted average number of common shares outstanding:
Basic and diluted	3,306	2,886	3,192	2,812

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash Flows From Operating Activities:
Net loss	$ (3,780)	$ (3,599)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	39	37
Amortization	157	$ 100
Accretion of contract liability	13
Increase (decrease) in allowance for doubtful accounts	(293)	$ 390
Provision for inventory reserve	371	146
Stock-based compensation	$ 730	1,227
Impairment charge		5
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable	$ 660	(1,086)
(Increase) decrease in inventories	(371)	(1,955)
Decrease in prepaid expenses and other current assets	274	22
Increase in accounts payable and accrued expenses	229	46
Net cash used in operating activities	(1,971)	(4,667)
Cash Flows From Investing Activities:
Additions to fixed assets	$ (27)	(23)
Acquisition of intangible assets		(6)
Net cash used in investing activities	$ (27)	(29)
Cash Flows From Financing Activities:
Borrowings under revolving note, net	400	$ 220
Repayments of term note	(100)
Proceeds from exercise of warrants, net	$ 916
Proceeds from issuance of common stock		$ 4,735
Offering costs		(72)
Net cash provided by financing activities	$ 1,216	4,883
Net increase (decrease) in cash	(782)	187
Cash at beginning of period	1,567	451
Cash at end of period	785	$ 638
Cash paid during the period for:
Interest	11
Income taxes, net of refunds	$ 4	$ 2
Supplemental schedule of non-cash investing and financing activities:
Shares issued for private placement fee		355
Warrants issued with common stock		2,486
Forfeiture of restricted stock for prepaid services		70
Patent acquired in exchange for royalties obligation		$ 101
Incremental fair value resulting from warrant modification	$ 225
Conversion of revolving note to term note	$ 400

Nature of Operations, Basis of

Nature of Operations, Basis of Presentation and Liquidity	9 Months Ended
	Sep. 30, 2015
Nature of Operations, Basis of Presentation and Liquidity [Abstract]
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY	NOTE 1 – NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY Nature of Operations MYOS Corporation is an emerging bionutrition and biotherapeutics company focused on the discovery, development and commercialization of products that improve muscle health and function. The Company was incorporated under the laws of the State of Nevada on April 11, 2007. As used in this report, the terms “the Company”, “MYOS”, “our”, or “we”, refer to MYOS Corporation, its predecessor, Atlas Therapeutics Corporation, and subsidiary, unless the context indicates otherwise. On February 25, 2011, the Company entered into an agreement to acquire the intellectual property for Fortetropin ® Our commercial focus is to leverage our clinical data to develop proprietary products including direct-to-consumer branded products using multiple product delivery formats to target the large, but currently underserved, markets focused on muscle health. The sales channels through which we sell our products have changed significantly over the past year. Our first commercial product, MYO-T12, is sold in the sports nutrition market under the brand name MYO-X ® TM For the three months ended September 30, 2015, direct sales and distributor sales were $36 and $0, respectively. For the three months ended September 30, 2014, direct sales and distributor sales were $7 and $100, respectively. For the nine months ended September 30, 2015, direct sales and distributor sales were $57 and $67, respectively. For the nine months ended September 30, 2014, direct sales and distributor sales were $17 and $3,315, respectively. We continue to pursue additional distribution arrangements and direct sales of our Rē Muscle Health TM TM Liquidity As of September 30, 2015, the Company had cash of $785 to meet current obligations. We have incurred net losses since our inception. For the three and nine month periods ended September 30, 2015 our net loss was $1,294 and $3,780, respectively. In addition, net cash used in operating activities for the nine months ended September 30, 2015 was $1,971. At September 30, 2015 our accumulated deficit was $22,147. Since the Company’s inception, net cash provided by financing activities, which has been our primary source of cash flows, was $16,561. At September 30, 2015, we had outstanding borrowings of $300 under our Term Note (as defined below), which matures on December 31, 2015 (See NOTE 6). As of the filing date of this Form 10-Q, management believes that there is not sufficient capital resources from operations and existing financing arrangements in order to meet operating expenses and working capital requirements for the next twelve months. We will need to seek additional funding through public or private financing or through collaborative arrangements with strategic partners in the fourth quarter of 2015, as we do not expect to have sufficient cash to operate past such quarter. These facts raise substantial doubt about the Company’s ability to continue as a going concern. Management’s Plans We are evaluating various alternatives, including reducing operating expenses, such as personnel costs, securing additional financing for future business activities and other strategic alternatives. There can be no assurance that additional sources of financing will be available on acceptable terms, if at all. If no additional sources of financing are available, our future operating prospects will be adversely affected. No adjustments have been made to these financial statements to reflect this uncertainty. Basis of Presentation The accompanying condensed consolidated balance sheet as of December 31, 2014, which has been derived from our audited financial statements, and the unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and disclosures required by U.S. GAAP for complete consolidated financial statements have been condensed or omitted herein. The interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Form 10-K for the year ended December 31, 2014. The unaudited interim condensed consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The Company is responsible for the unaudited interim condensed consolidated financial statements included in this report. The results of operations of any interim period are not necessarily indicative of the results for the full year.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements include the accounts of MYOS Corporation and its wholly-owned subsidiary, Atlas Acquisition Corp. All material intercompany balances and transactions have been eliminated. Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, equity and the disclosures of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates. Significant items subject to such estimates include but are not limited to the valuation of stock-based awards, revenue recognition, measurement of allowances for doubtful accounts and inventory reserves, the selection of asset useful lives, fair value estimations used to test long-lived assets, including intangibles, impairments and provisions necessary for assets and liabilities. The Company has recorded minimal sales to its distributors during the past five consecutive quarters, and has only recently launched its Rē Muscle Health portfolio of branded products. Accordingly, the Company cannot predict future sales. Management’s estimates, including evaluation of impairment of long-lived assets and inventory reserves are based in part on forecasted future results. A variety of factors could cause actual results to differ from forecasted results and these differences could have a significant effect on asset carrying amounts. Cash & Cash Equivalents As of September 30, 2015 and December 31, 2014, the Company had cash of $785 and $1,567, respectively. The Company considers all highly liquid investments purchased with a maturity of three months or less and money market accounts to be cash equivalents. At September 30, 2015 and December 31, 2014, the Company had no cash equivalents. The Company maintains its bank accounts with high credit quality financial institutions and has never experienced any losses related to these bank accounts. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its financial institutions. The balance at times may exceed federally insured limits. Concentrations of Risk, Significant Customers and Significant Supplier Management regularly reviews accounts receivable and if necessary, establishes an allowance for doubtful accounts that reflects management’s best estimate of amounts that may not be collectible based on historical collection experience and specific customer information. Bad debt expense recognized as a result of an allowance for doubtful accounts is classified under selling, general and administrative expenses in the statements of operations. Based on historical collection experience and other factors, during the three months ended September 30, 2015, management determined that the Cenegenics’ allowance for doubtful accounts should be reduced to $97. Accordingly, a reduction in bad debt expense of $98 and $293 was recorded for the three and nine months ended September 30, 2015, respectively. Bad debt expense was $390 for the three and nine months ended September 30, 2014. If we are unable to collect our outstanding accounts receivable from Cenegenics, our operating results and financial condition will be adversely affected. At September 30, 2015 and December 31, 2014, the Company had the following concentrations of accounts receivable with customers: (In thousand $) September 30, December 31, 2015 2014 Cenegenics $ 700 $ 1,372 Other 12 - Subtotal 712 1,372 Allowance for doubtful accounts (97 ) (390 ) Accounts receivable, net $ 615 $ 982 The Company currently relies on one third-party manufacturer to produce Fortetropin (see NOTE 12 – Commitments and Contingencies - Supply Agreement). This manufacturer purchases all the needed raw materials from suppliers and coordinates any additional production steps with third-parties. We have multiple vendors for blending, packaging and labeling. The Company is pursuing other supply alternatives. Inventories Inventories are valued at the lower of cost or market, with cost determined on a first in, first-out basis. Fixed Assets Fixed assets are stated at cost and depreciated to their estimated residual value over their estimated useful lives of 3 to 7 years. Leasehold improvements are amortized over the lesser of the asset's useful life or the contractual remaining lease term including expected renewals. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are reversed from the accounts and the resulting gains or losses are included in the statements of operations. Depreciation is provided using the straight-line method for all fixed assets. We review our fixed assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. We use an estimate of future undiscounted net cash flows of the related assets or groups of assets over their remaining lives in measuring whether the assets are recoverable. If the assets are determined to be unrecoverable, an impairment loss is calculated by determining the difference between the carrying values and the estimated fair value. During the nine months ended September 30, 2014, the Company recorded an impairment charge of $5 to reduce the unrecoverable net carrying value of a capitalized fixed asset to zero. We did not consider any of our fixed assets to be impaired during the three and nine months ended September 30, 2015. Intangible Assets The Company’s intangible assets consist primarily of intellectual property pertaining to Fortetropin, including its formula, trademarks, trade secrets, patent application and domain names, which was determined to have a fair value of $2,000 as of December 31, 2011. Based on expansion into new markets and introduction of new formulas, management determined that the intellectual property had a finite useful life of ten (10) years and began amortizing the asset over its estimated useful life beginning April 2014. Based on five consecutive quarters of minimal revenues combined with changes in the sales channels through which the Company sells its products (i.e., a shift to a commercial model focused on direct-to-consumer sales of branded products) along with an inability to predict future orders, if any, from MHP or Cenegenics or to what extent we will be able to secure new distribution arrangements, we tested the intellectual property for impairment in the third quarter of 2015 and determined that the asset value was recoverable and therefore no impairment was recognized. This determination was in part based on the Company’s expectation that it will be successful in raising additional capital resources. In July 2014, the Company acquired the United States patent application for the manufacture of Fortetropin from Intangible assets also includes patent costs associated with applying for a patent and being issued a patent. Costs to defend a patent and costs to invalidate a competitor’s patent or patent application are expensed as incurred. Upon issuance of the patent, capitalized patent costs are reclassified from intangibles with indefinite lives to intangibles with finite lives and amortized on a straight-line basis over the shorter of the estimated economic life or the initial term of the patent, generally 20 years. Intangible assets at September 30, 2015 and December 31, 2014 consisted of the following: (In thousand $) September 30, December 31, 2015 2014 Intangibles with finite lives: Intellectual property $ 2,101 $ 2,101 Less: accumulated amortization (312 ) (155 ) Total intangibles with finite lives: 1,789 1,946 Intangibles with indefinite lives: Intellectual property - - Patent costs 44 44 Total intangibles with indefinite lives: 44 44 Total intangible assets, net $ 1,833 $ 1,990 Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense for intangible assets is estimated to be $53 over the remainder of 2015 and $210 Impairment testing of intangible assets subject to amortization involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using a discounted future cash flow method. The computed impairment loss is recognized in the period that the impairment occurs. Assets which are not impaired may require an adjustment to the remaining useful lives for which to amortize the asset. Impairment testing requires the development of significant estimates and assumptions involving the determination of estimated net cash flows, selection of the appropriate discount rate to measure the risk inherent in future cash flow streams, assessment of an asset’s life cycle, competitive trends impacting the asset as well as other factors. Changes in these underlying assumptions could significantly impact the asset’s estimated fair value. Revenue Recognition The Company records revenue from product sales when persuasive evidence of an arrangement exists, product has been shipped or delivered, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. Product sales represent revenue from the sale of products and related shipping amounts billed to customers, net of promotional discounts, rebates, and return allowances. Depending on individual customer agreements, sales are recognized either upon shipment of product to customers or upon delivery. With respect to direct-to-consumer sales, both title and risk of loss transfer to customers upon our delivery to the customer. The Company’s gross product sales may be subject to sales allowances and deductions in arriving at reported net product sales. For example, we may periodically offer discounts and sales incentives to customers to encourage purchases. Sales incentives are treated as a reduction to the purchase price of the related transaction. Reductions from gross sales for customer discounts and rebates have been minimal, and sales allowances for product returns have not been provided, since under our existing arrangements, customers are not permitted to return product except for non-conforming product. Research and Development Research and development expenses consist primarily of salaries, benefits, and other related costs, including stock-based compensation, for personnel serving in our research and development functions, and other internal operating expenses, the cost of manufacturing our product for clinical study, the cost of conducting clinical studies and the cost of conducting preclinical and research activities. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are initially capitalized and are then recognized as an expense as the related goods are consumed or the services are performed. Shipping and Handling Costs The Company records costs for shipping and handling of products to our customers in cost of sales. These expenses were $4 and $0 for the three months ended September 30, 2015 and 2014, respectively, and $8 and $10 for the nine months ended September 30, 2015 and 2014 respectively. Stock-based Compensation Generally, stock-based payments are measured at their estimated fair value on the date of grant. Stock-based awards to non-employees are re-measured at fair value each financial reporting date until performance is completed. Stock-based compensation expense recognized during a period is based on the estimated number of awards that are ultimately expected to vest. For stock options and restricted stock that do not vest immediately but which contain only a service vesting feature, we recognize compensation cost on the unvested shares and options on a straight-line basis over the remaining vesting period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of options and the market price of our common stock on the date of grant for the fair value of restricted stock issued. Our determination of fair value of stock-based awards is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and certain other market variables such as the risk-free interest rate. Comprehensive Loss Comprehensive income (loss) includes all changes in equity during a period except those that resulted from investments by, or distributions to, the Company’s stockholders. Other comprehensive income (loss) refers to revenues, expenses, gains and losses that are included in comprehensive income (loss), but excluded from net loss as these amounts are recorded directly as an adjustment to stockholders’ equity. The Company had no items of other comprehensive income (loss) for the three and nine months ended September 30, 2015 and 2014. Accordingly, the Company's comprehensive loss and net loss are the same for all periods presented. Segment Information Accounting Standards Codification (“ASC”) 280, Disclosures about Segments of an Enterprise and Related Information Fair Value Measurement Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby observable and unobservable inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchy levels of inputs to measure fair value: Level 1 Inputs that utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 Inputs that utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active. Level 3: Inputs that utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity. A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement. At September 30, 2015 and December 31, 2014, the Company’s financial instruments consist primarily of cash, accounts receivable, accounts payable and accrued expenses. Due to their short-term nature, the carrying amounts of the Company’s financial instruments approximated their fair values. Basic and Diluted Earnings (Loss) Per Share Basic net loss per share is computed by dividing net loss available to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potential dilutive securities outstanding had been issued. The Company uses the “treasury stock” method to determine the dilutive effect of common stock equivalents such as options, warrants and restricted stock. For the three and nine months ended September 30, 2015 and 2014, the Company incurred a net loss. Accordingly, the Company’s common stock equivalents were anti-dilutive and excluded from the diluted net loss per share computation. The aggregate number of potentially dilutive common stock equivalents outstanding at September 30, 2015 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 1,410,673, which includes up to 193,865 Make-Whole Shares (See NOTE 9 – Warrants), warrants to purchase an aggregate 761,878 shares of common stock, options to purchase an aggregate of 443,480 shares of common stock and unvested restricted stock awards of 11,450 shares of common stock. The aggregate number of potentially dilutive common stock equivalents outstanding at September 30, 2014 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 866,102, which includes warrants to purchase an aggregate 473,522 shares of common stock, options to purchase an aggregate of 369,880 shares of common stock and unvested restricted stock awards of 22,700 shares of common stock. Income Taxes Income taxes are accounted for under the asset and liability method in accordance with ASC 740, “Accounting for Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance to the extent that the recoverability of the asset is unlikely to be recognized. The Company follows ASC 740 rules governing uncertain tax positions, which provides guidance for recognition and measurement. This prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. It also provides accounting guidance on recognition, classification and disclosure of these uncertain tax positions. The Company has no uncertain income tax positions. Interest costs and penalties related to income taxes are classified as interest expense and operating expenses, respectively, in the Company's financial statements. For the three and nine months ended September 30, 2015 and 2014, the Company did not recognize any interest or penalty expense related to income taxes. The Company files income tax returns in the U.S. federal jurisdiction and states in which it does business. Immaterial Correction of Prior Period Presentation Revised loss per share for the three and six month period ended June 30, 2015 was as follows: (In thousand $) Three Months Ended Six Months Ended June 30, June 30, Net loss attributable to common shareholders, as reported $ (957 ) $ (2,486 ) Less: deemed dividend resulting from warrant modification (225 ) (225 ) Net loss attributable to common shareholders, as revised $ (1,182 ) $ (2,711 ) Net loss per share attributable to common shareholders: Basic and diluted, as reported $ (0.30 ) $ (0.79 ) Basic and diluted, as revised $ (0.37 ) $ (0.87 ) Weighted average number of common shares outstanding: Basic and diluted 3,182 3,133

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2015
Recent Accounting Pronouncements [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	NOTE 3 – RECENT ACCOUNTING PRONOUNCEMENTS In August 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2015-15, Interest—Imputation of Interest (Subtopic 835-30), Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements — Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (SEC Update) ("ASU 2015-15"). ASU 2015-15 clarifies that as line of credit arrangements were not specifically discussed in ASU 2015-03, companies can continue to present debt issuance costs for line of credit arrangements as an asset and subsequently amortize the deferred issuance cost ratably over the term of the arrangement. The amendments in ASU 2015-15 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory (“ASU 2015-11”) which changes the measurement principle for inventory from the lower of cost or market to the lower of cost and net realizable value. ASU 2015-11 defines net realizable value as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The new guidance must be applied on a prospective basis and is effective for periods beginning after December 15, 2016, with early adoption permitted. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures. In April 2015, the FASB issued ASU No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”), which requires all debt issuance costs be presented in the balance sheet as a direct deduction from the carrying value of the associated debt. Prior to the issuance of this standard, debt issuance costs, which are specific incremental costs, other than those paid to the lender, that are directly attributable to issuing a debt instrument (i.e., third party costs), were required to be presented in the balance sheet as a deferred charge (i.e., an asset). Under ASU 2015-03, the presentation of debt issuance costs is consistent with the presentation for a debt discount, (i.e., a direct adjustment to the carrying value of the debt). ASU 2015-03 does not affect the recognition and measurement of debt issuance costs. Accordingly, the amortization of such costs should continue to be calculated using the interest method and be reported as interest expense. ASU 2015-03 is effective for us in financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). The amendments in this update define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and provides related footnote disclosure requirements. Under U.S. GAAP, financial statements are prepared under the presumption that the reporting organization will continue to operate as a going concern, except in limited circumstances. Financial reporting under this presumption is commonly referred to as the going concern basis of accounting. The going concern basis of accounting establishes the fundamental basis for measuring and classifying assets and liabilities. This update provides guidance on when there is substantial doubt about an organization’s ability to continue as a going concern and how the underlying conditions and events should be disclosed in the footnotes. It is intended to reduce diversity that existed in footnote disclosures because of the lack of guidance about when substantial doubt existed. The amendments in this update are effective for us beginning in the first quarter of 2017. Early application is permitted. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”). ASU 2014-09 supersedes nearly all existing revenue recognition guidance under U.S. GAAP and requires revenue to be recognized when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for us beginning in the first quarter of 2018 using one of two prescribed transition methods. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.

Inventories, Net

Inventories, Net	9 Months Ended
	Sep. 30, 2015
Inventories, Net [Abstract]
INVENTORIES, NET	NOTE 4 – INVENTORIES, NET Inventories, net at September 30, 2015 and December 31, 2014 consisted of the following: (In thousand $) September 30, December 31, 2015 2014 Raw materials $ 2,008 $ 1,638 Work in process 1 2 Finished goods 187 443 2,196 2,083 Less: inventory reserves (382 ) (269 ) Inventories, net $ 1,814 $ 1,814

Fixed Assets

Fixed Assets	9 Months Ended
	Sep. 30, 2015
Fixed Assets [Abstract]
FIXED ASSETS	NOTE 5 – FIXED ASSETS Fixed assets at September 30, 2015 and December 31, 2014 consisted of the following: (In thousand $) September 30, December 31, 2015 2014 Furniture, fixtures and equipment $ 116 $ 134 Computers and software 66 21 Leasehold improvements 239 239 Other 7 7 Total fixed assets 428 401 Less: accumulated depreciation and amortization (127 ) (88 ) Net book value of fixed assets $ 301 $ 313 Depreciation and amortization expense was $14 and $13 for the three months ended September 30, 2015 and 2014, respectively and $39 and $37 for the nine months ended September 30, 2015 and 2014, respectively. Repairs and maintenance costs are expensed as incurred.

Debt

Debt	9 Months Ended
	Sep. 30, 2015
Debt [Abstract]
DEBT	NOTE 6 – DEBT Term Note On September 10, 2015, the Company converted its outstanding revolving note with City National Bank, which had a termination date of August 31, 2015, into a term note (the “Term Note”). The Term Note provides that the then outstanding balance of $400 shall be payable along with interest thereon on the last day of each month in four (4) consecutive installments of $100, with the final installment due and payable in full on December 31, 2015. The Term Note is collateralized by all inventory, chattel paper, accounts, equipment, general intangibles, securities and instruments. The Term Note contains customary events of default, including failure to make payment and bankruptcy. The outstanding principal balance under the Term Note bears interest at a per annum interest rate equal to the greater of 3.50%, or prime rate plus 1.25%. As of September 30, 2015, the interest rate on the Term Note was 4.50%. At September 30, 2015, the balance under the Term Note was $300. As of the date of this Form 10-Q, the Company has made all payments of principal and interest when due under the Term Note.

Prepaid Expenses, Other Current

Prepaid Expenses, Other Current Assets, Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2015
Prepaid Expenses Other Current Assets Accrued Expenses and Other Current Liabilities [Abstract]
PREPAID EXPENSES, OTHER CURRENT ASSETS, ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	NOTE 7 - PREPAID EXPENSES, OTHER CURRENT ASSETS, ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of various payments that the Company has made in advance for goods or services to be received in the future. Prepaid expenses and other current assets at September 30, 2015 and December 31, 2014 consisted of the following: (In thousand $) September 30, December 31, 2015 2014 Prepaid insurance $ 56 $ 46 Prepaid research and development - 15 Prepaid consulting - 8 Prepaid inventory purchases 250 664 Deferred charges (1) 153 - Other 12 12 Total prepaid expenses and other current assets $ 471 $ 745 (1) Deferred charges represents the cost of inventory shipped to a customer in May 2015. The shipment was related to a settlement agreement with the customer under which there were extended payment terms. Accordingly the Company has deferred the charges until payment of the commensurate sale is received from the customer and revenue is recognized. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of estimated future liability payments that relate to the current and prior accounting periods. Management reviews these estimates regularly to determine their reasonableness. Accrued expenses and other liabilities at September 30, 2015 and December 31, 2014 consisted of the following: (In thousand $) September 30, December 31, 2015 2014 Advertising and promotional expense payable $ 171 $ 171 Audit fees payable 60 25 Deferred rent 50 30 Deferred revenue (1) 228 - Research and development - 49 Accrued salaries and bonuses 38 92 Consulting fees payable 15 96 Other accrued expenses 12 32 Total accrued expenses and other current liabilities $ 574 $ 495 (1) Deferred revenue represents additional revenue to be recognized in connection with inventory shipped to a customer in May 2015. The shipment was related to a settlement agreement with the customer under which there were extended payment terms. Accordingly the Company has deferred the revenue until the related receivable is collected from the customer.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 8 – STOCKHOLDERS’ EQUITY Changes in stockholders’ equity for the nine months ended September 30, 2015 were as follows: (In thousand $) Additional Total Common Stock paid-in Accumulated stockholders' Shares Amount capital deficit equity Balance at December 31, 2014 3,103,300 $ 3 $ 25,100 $ (18,367 ) $ 6,736 Shares issued for services, net (1) 24,000 - 101 - 101 Stock-based compensation expense - - 629 - 629 Exercise of Series D Warrants, net 190,609 - 916 - 916 Net loss - - - (3,780 ) (3,780 ) Balance at September 30, 2015 3,317,909 $ 3 $ 26,746 $ (22,147 ) $ 4,602 (1) Represents 25,000 shares of fully vested restricted common stock issued to a consultant for services, partially offset by the forfeiture of 1,000 shares of restricted common stock previously issued to another consultant. Issuances of Common Stock The Company has periodically issued common stock in connection with private and public offerings transactions. The Company has received aggregate gross proceeds of approximately $16.9 million from these transactions as follows: (In thousand $) Gross Date Shares Proceeds February 25, 2011 95,334 $ 1,430 May 31, 2011 28,200 423 June 27, 2011 37,500 563 July 12, 2011 1,667 25 December 2, 2011 4,000 40 February 10, 2012 65,000 325 February 14, 2012 80,000 400 March 7, 2012 20,000 100 March 15, 2012 35,000 175 March 22, 2012 5,000 25 April 9, 2012 20,000 100 April 24, 2012 * 4,000 - June 28, 2012 48,000 600 July 6, 2012 411,600 5,145 January 27, 2014 631,346 4,735 November 19, 2014 193,865 1,816 May 18, 2015 190,609 1,001 1,871,121 $ 16,903

Warrants

Warrants	9 Months Ended
	Sep. 30, 2015
Warrants [Abstract]
WARRANTS	NOTE 9 - WARRANTS On January 27, 2014, in connection with a private placement transaction, the Company granted warrants to purchase an aggregate of 473,522 shares of common stock as follows: (i) Series A warrants to purchase 315,676 shares of common stock at an exercise price of $15.00 per share (the “Series A Warrant”) and (ii) Series B warrants to purchase 157,846 shares of common stock at an exercise price of $45.00 per share (the “Series B Warrant”). The warrants were determined to have an estimated aggregate fair value of $2,486 at issuance. The Series A Warrants entitle the holders to purchase shares of common stock for a period of three years from the grant date and the Series B Warrants entitle the holders to purchase common stock for a period of five years from the grant date. The warrants can also be exercised on a cashless basis. On November 19, 2014 in connection with a registered direct public offering, the Company granted warrants to purchase an aggregate of 484,663 shares of common stock as follows: (i) Series C warrants entitle the holders to purchase an aggregate of 145,399 shares of common stock at an exercise price of $12.00 per share for a period of 66-months from the grant date (the “Series C Warrant”), (ii) Series D warrants entitle the holders to purchase an aggregate of 193,865 shares of common stock at an exercise price of $9.37 per share for a period of 6-months from the grant date (the “Series D Warrant”), and (iii) Series E warrants entitle the holders to purchase an aggregate of 145,399 shares of common stock at an exercise price of $15.00 per share for a period of 90-months from the grant date (the “Series E Warrant). Each Series E Warrant will be exercisable only if the Series D Warrants are exercised. The Series C, Series D and Series E Warrants were determined to have an estimated aggregate fair value of $969, $470, and $1,048 at issuance, respectively. Expected volatility 96%-227 % Risk-free interest rate 0.02%-1.87 % Expected term in years 0.0-7.0 Expected dividend yield 0 % The risk-free rate is based on the U.S. Treasury rate for a note with a similar term in effect at the time of the grant. The expected volatility is based on the volatility of the Company’s historical stock price. At May 18, 2015, the modified Series C and Series E Warrants were determined to have an estimated aggregate fair value of $569 and $653, respectively. A total of 3,256 Series D Warrants not presented for exercise by May 21, 2015 expired unexercised, along with 2,442 Series E Warrants, which became exercisable only if the Series D Warrants were exercised. The following table summarizes information about warrants outstanding and exercisable at September 30, 2015: Description Grant Date Number of Shares Underlying Warrants Originally Granted Shares Underlying Warrants Exchanged, Exercised or Expired Shares Underlying Warrants Outstanding and Exercisable at September 30, Exercise Price Expiration Term in Years Series A (1) January 27, 2014 315,676 - 315,676 $ 15.00 1.33 Series B (1) January 27, 2014 157,846 - 157,846 $ 45.00 3.32 Series C (2) November 19, 2014 145,399 (142,957 ) 2,442 $ 12.00 4.63 142,957 142,957 $ 9.00 4.63 Series D (2) November 19, 2014 193,865 (193,865 ) - N/A N/A Series E (2) November 19, 2014 145,399 (145,399 ) - N/A N/A 142,957 142,957 $ 9.00 6.63 958,185 (196,307 ) 761,878 (1) Issued in connection with the January 27, 2014 private placement transaction. (2) Issued in connection with the November 19, 2014 registered-direct public offering, and subsequently revised pursuant to Warrant Exercise Agreements entered into on May 18, 2015.

Stock Compensation

Stock Compensation	9 Months Ended
	Sep. 30, 2015
Stock Compensation [Abstract]
STOCK COMPENSATION	NOTE 10 - STOCK COMPENSATION The Company’s 2012 Equity Incentive Plan (as amended, the “Plan”) provides for the issuance of up to 550,000 shares of our common stock. The Plan provides for grants of stock options, stock appreciation rights, restricted stock, other stock-based awards and other cash-based awards. As of September 30, 2015, the remaining shares of common stock available for future issuance of awards was 136,520. The Company granted an aggregate of 30,000 options to purchase restricted common stock to certain directors prior to the adoption of the Plan. Stock Option The following table summarizes stock option activity for the nine months ended September 30, 2015: Weighted Weighted Average Shares Average Remaining Under Exercise Contractual Options Price Term (Years) Balance at December 31, 2014 367,080 $ 14.68 8.50 Options granted 108,000 12.50 Options exercised - - Options cancelled/expired/forfeited (31,600 ) (11.92 ) Balance at September 30, 2015 443,480 $ 14.43 8.09 The weighted average grant date fair value of stock options granted during the nine months ended September 30, 2015 was $5.22. The following table summarizes the assumptions used to value stock options granted during the nine months ended September 30, 2015 using a Black-Scholes model: Expected volatility 98 % Risk-free interest rate 1.39%-1.69 % Expected term in years 5.8-6.3 Expected dividend yield 0 % The risk-free rate is based on the U.S. Treasury rate for a note with a similar term in effect at the time of the grant. The expected volatility is based on the volatility of the Company’s historical stock price. At September 30, 2015, the aggregate intrinsic value of outstanding and exercisable options was $0. The aggregate intrinsic value is calculated by multiplying the number of outstanding and exercisable options by the excess of the market price for our common stock at September 30, 2015 over the exercise price for each option. At September 30, 2015, the market price for our common stock was $2.68. The following table summarizes information about options outstanding and exercisable at September 30, 2015: Options Outstanding Options Exercisable Weighted Average Weighted Average Range of Remaining Range of Remaining Exercise Options Contractual Exercise Options Contractual $ 7.00 5,000 6.64 $ 7.00 5,000 6.64 $ 8.60 28,500 8.45 $ 8.60 21,875 8.45 $ 10.00 5,120 7.36 $ 10.00 5,120 7.36 $ 11.00 3,000 7.28 $ 11.00 3,000 7.28 $ 12.10 30,500 8.61 $ 12.10 15,250 8.61 $ 12.50 188,800 8.51 $ 12.50 92,800 7.73 $ 12.55 20,000 8.64 $ 12.55 5,000 8.64 $ 13.00 14,600 8.78 $ 13.00 7,300 8.78 $ 13.45 2,000 8.73 $ 13.45 500 8.73 $ 13.50 14,960 8.74 $ 13.50 3,740 8.74 $ 13.75 6,000 8.93 $ 13.75 3,000 8.93 $ 17.50 100,000 7.36 $ 17.50 100,000 7.36 $ 22.50 5,000 5.87 $ 22.50 5,000 5.87 $ 32.00 15,000 5.78 $ 32.00 15,000 5.78 $ 34.50 5,000 5.81 $ 34.50 5,000 5.81 443,480 287,585 As of September 30, 2015, there were 155,895 remaining unvested options, with vesting terms ranging from 0.1 to 3.3 years. As of September 30, 2015, vested options had a weighted-average remaining contractual term of 7.6 years and a weighted-average exercise price of $15.38 per share. Restricted Stock The following table summarizes restricted stock awards activities for the nine months ended September 30, 2015: Weighted Average Grant Date Shares Share Price Restricted stock awards unvested at December 31, 2014 22,200 $ 14.95 Granted 25,000 4.04 Vested (34,750 ) 7.77 Forfeited (1,000 ) 7.50 Restricted stock awards unvested at September 30, 2015 11,450 $ 13.55 At September 30, 2015, the weighted-average remaining vesting period of unvested restricted stock awards was 1.5 years. Stock-Based Compensation: Stock-based compensation was $165 and $502 for the three months ended September 30, 2015 and 2014, respectively, and $730 and $1,227 for the nine months ended September 30, 2015 and 2014, respectively. Stock-based compensation consists of expenses related to the issuance of stock options and restricted stock. The following table summarizes the components of stock-based compensation included in the statements of operations for the three and nine months ended September 30, 2015 and 2014: (In thousand $) Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Cost of sales $ - $ - $ - $ - Research & development 25 36 75 100 Selling, general and administrative 140 466 655 1,127 Total stock-based compensation $ 165 $ 502 $ 730 $ 1,227 The aggregate unrecognized compensation expense of stock options and restricted stock at September 30, 2015 was $1,018 which will be recognized through January 2019.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Taxes [Abstract]
INCOME TAXES	NOTE 11 - INCOME TAXES Due to the Company’s history of losses and uncertainty of future taxable income, a valuation allowance has been established to fully offset net operating losses and other deferred tax assets. The valuation allowance will be maintained until sufficient positive evidence exists to support that it is no longer necessary. The Company is liable for various state minimum taxes which are immaterial.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 12 - COMMITMENTS AND CONTINGENCIES Operating Lease The Company leases its corporate offices under an operating lease. The term of the lease is five years commencing on January 1, 2015 and expiring on December 31, 2019. We have two options to renew our lease for an additional three years each. At September 30, 2015, the future minimum lease payments under the non-cancellable operating lease in excess of one year is as follows: (In thousand $) Years Ended December 31, Amount 2015 (remaining three months) $ 45 2016 152 2017 181 2018 187 2019 191 Total $ 756 Rent expense, including common area maintenance charges and taxes, was $61 and $20 for the three months ended September 30, 2015 and 2014, respectively, and $172 and $56 for the nine months ended September 30, 2015 and 2014, respectively. Defined Contribution Plan The Company established a 401(K) Plan (the “401(K) Plan”) for eligible employees of the Company effective April 1, 2014. Generally, all employees of the Company who are at least twenty-one years of age and who have completed three months of service are eligible to participate in the 401(K) Plan. The 401(K) Plan is a defined contribution plan that provides that participants may make salary deferral contributions, of up to the statutory maximum allowed by law (subject to make-up contributions) in the form of voluntary payroll deductions. The Company’s matching contribution is equal to 100 percent on the first four percent of a participant’s compensation which is deferred as an elective deferral. The Company’s aggregate matching contribution were $10 and $9 for the three months ended September 30, 2015 and 2014, respectively, and $37 and $16 for the nine months ended September 30, 2015 and 2014, respectively. Supply Agreement Pursuant to the Exclusive Supply Agreement (as amended, the “Agreement”) with DIL , DIL manufactures and supplies Fortetropin exclusively to the Company and may not manufacture Fortetropin for other entities. In exchange the Company agreed to purchase minimum quantities of Fortetropin at fixed prices through 2016. In addition, DIL agreed to assign its United States patent application for the manufacture of the formula to the Company and the Company agreed, for a period of seven years from the expiration of the Agreement, it will pay DIL a low single-digit royalty payment for each kilogram of Fortetropin produced by the Company, subject to certain minimum and maximum amounts. DIL also granted the Company a right of first refusal to license and/or acquire the European patent it owns for the manufacture of the formula. The Agreement expires on December 31, 2016, and may be renewed for additional one-year periods unless terminated by either party by giving a ninety day notice before the expiration of the current term € € €1,296 €

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Summary of Significant Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements include the accounts of MYOS Corporation and its wholly-owned subsidiary, Atlas Acquisition Corp. All material intercompany balances and transactions have been eliminated.
Estimates	Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, equity and the disclosures of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates. Significant items subject to such estimates include but are not limited to the valuation of stock-based awards, revenue recognition, measurement of allowances for doubtful accounts and inventory reserves, the selection of asset useful lives, fair value estimations used to test long-lived assets, including intangibles, impairments and provisions necessary for assets and liabilities. The Company has recorded minimal sales to its distributors during the past five consecutive quarters, and has only recently launched its Rē Muscle Health portfolio of branded products. Accordingly, the Company cannot predict future sales. Management’s estimates, including evaluation of impairment of long-lived assets and inventory reserves are based in part on forecasted future results. A variety of factors could cause actual results to differ from forecasted results and these differences could have a significant effect on asset carrying amounts.
Cash & Cash Equivalents	Cash & Cash Equivalents As of September 30, 2015 and December 31, 2014, the Company had cash of $785 and $1,567, respectively. The Company considers all highly liquid investments purchased with a maturity of three months or less and money market accounts to be cash equivalents. At September 30, 2015 and December 31, 2014, the Company had no cash equivalents. The Company maintains its bank accounts with high credit quality financial institutions and has never experienced any losses related to these bank accounts. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its financial institutions. The balance at times may exceed federally insured limits.
Concentrations of Risk, Significant Customers and Significant Supplier	Concentrations of Risk, Significant Customers and Significant Supplier Management regularly reviews accounts receivable and if necessary, establishes an allowance for doubtful accounts that reflects management’s best estimate of amounts that may not be collectible based on historical collection experience and specific customer information. Bad debt expense recognized as a result of an allowance for doubtful accounts is classified under selling, general and administrative expenses in the statements of operations. Based on historical collection experience and other factors, during the three months ended September 30, 2015, management determined that the Cenegenics’ allowance for doubtful accounts should be reduced to $97. Accordingly, a reduction in bad debt expense of $98 and $293 was recorded for the three and nine months ended September 30, 2015, respectively. Bad debt expense was $390 for the three and nine months ended September 30, 2014. If we are unable to collect our outstanding accounts receivable from Cenegenics, our operating results and financial condition will be adversely affected. At September 30, 2015 and December 31, 2014, the Company had the following concentrations of accounts receivable with customers: (In thousand $) September 30, December 31, 2015 2014 Cenegenics $ 700 $ 1,372 Other 12 - Subtotal 712 1,372 Allowance for doubtful accounts (97 ) (390 ) Accounts receivable, net $ 615 $ 982 The Company currently relies on one third-party manufacturer to produce Fortetropin (see NOTE 12 – Commitments and Contingencies - Supply Agreement). This manufacturer purchases all the needed raw materials from suppliers and coordinates any additional production steps with third-parties. We have multiple vendors for blending, packaging and labeling. The Company is pursuing other supply alternatives.
Inventories	Inventories Inventories are valued at the lower of cost or market, with cost determined on a first in, first-out basis.
Fixed Assets	Fixed Assets Fixed assets are stated at cost and depreciated to their estimated residual value over their estimated useful lives of 3 to 7 years. Leasehold improvements are amortized over the lesser of the asset's useful life or the contractual remaining lease term including expected renewals. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are reversed from the accounts and the resulting gains or losses are included in the statements of operations. Depreciation is provided using the straight-line method for all fixed assets. We review our fixed assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. We use an estimate of future undiscounted net cash flows of the related assets or groups of assets over their remaining lives in measuring whether the assets are recoverable. If the assets are determined to be unrecoverable, an impairment loss is calculated by determining the difference between the carrying values and the estimated fair value. During the nine months ended September 30, 2014, the Company recorded an impairment charge of $5 to reduce the unrecoverable net carrying value of a capitalized fixed asset to zero. We did not consider any of our fixed assets to be impaired during the three and nine months ended September 30, 2015.
Intangible Assets	Intangible Assets The Company’s intangible assets consist primarily of intellectual property pertaining to Fortetropin, including its formula, trademarks, trade secrets, patent application and domain names, which was determined to have a fair value of $2,000 as of December 31, 2011. Based on expansion into new markets and introduction of new formulas, management determined that the intellectual property had a finite useful life of ten (10) years and began amortizing the asset over its estimated useful life beginning April 2014. Based on five consecutive quarters of minimal revenues combined with changes in the sales channels through which the Company sells its products (i.e., a shift to a commercial model focused on direct-to-consumer sales of branded products) along with an inability to predict future orders, if any, from MHP or Cenegenics or to what extent we will be able to secure new distribution arrangements, we tested the intellectual property for impairment in the third quarter of 2015 and determined that the asset value was recoverable and therefore no impairment was recognized. This determination was in part based on the Company’s expectation that it will be successful in raising additional capital resources. In July 2014, the Company acquired the United States patent application for the manufacture of Fortetropin from Intangible assets also includes patent costs associated with applying for a patent and being issued a patent. Costs to defend a patent and costs to invalidate a competitor’s patent or patent application are expensed as incurred. Upon issuance of the patent, capitalized patent costs are reclassified from intangibles with indefinite lives to intangibles with finite lives and amortized on a straight-line basis over the shorter of the estimated economic life or the initial term of the patent, generally 20 years. Intangible assets at September 30, 2015 and December 31, 2014 consisted of the following: (In thousand $) September 30, December 31, 2015 2014 Intangibles with finite lives: Intellectual property $ 2,101 $ 2,101 Less: accumulated amortization (312 ) (155 ) Total intangibles with finite lives: 1,789 1,946 Intangibles with indefinite lives: Intellectual property - - Patent costs 44 44 Total intangibles with indefinite lives: 44 44 Total intangible assets, net $ 1,833 $ 1,990 Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense for intangible assets is estimated to be $53 over the remainder of 2015 and $210 Impairment testing of intangible assets subject to amortization involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using a discounted future cash flow method. The computed impairment loss is recognized in the period that the impairment occurs. Assets which are not impaired may require an adjustment to the remaining useful lives for which to amortize the asset. Impairment testing requires the development of significant estimates and assumptions involving the determination of estimated net cash flows, selection of the appropriate discount rate to measure the risk inherent in future cash flow streams, assessment of an asset’s life cycle, competitive trends impacting the asset as well as other factors. Changes in these underlying assumptions could significantly impact the asset’s estimated fair value.
Revenue Recognition	Revenue Recognition The Company records revenue from product sales when persuasive evidence of an arrangement exists, product has been shipped or delivered, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. Product sales represent revenue from the sale of products and related shipping amounts billed to customers, net of promotional discounts, rebates, and return allowances. Depending on individual customer agreements, sales are recognized either upon shipment of product to customers or upon delivery. With respect to direct-to-consumer sales, both title and risk of loss transfer to customers upon our delivery to the customer. The Company’s gross product sales may be subject to sales allowances and deductions in arriving at reported net product sales. For example, we may periodically offer discounts and sales incentives to customers to encourage purchases. Sales incentives are treated as a reduction to the purchase price of the related transaction. Reductions from gross sales for customer discounts and rebates have been minimal, and sales allowances for product returns have not been provided, since under our existing arrangements, customers are not permitted to return product except for non-conforming product.
Research and Development	Research and Development Research and development expenses consist primarily of salaries, benefits, and other related costs, including stock-based compensation, for personnel serving in our research and development functions, and other internal operating expenses, the cost of manufacturing our product for clinical study, the cost of conducting clinical studies and the cost of conducting preclinical and research activities. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are initially capitalized and are then recognized as an expense as the related goods are consumed or the services are performed.
Shipping and Handling Costs	Shipping and Handling Costs The Company records costs for shipping and handling of products to our customers in cost of sales. These expenses were $4 and $0 for the three months ended September 30, 2015 and 2014, respectively, and $8 and $10 for the nine months ended September 30, 2015 and 2014 respectively.
Stock-based Compensation	Stock-based Compensation Generally, stock-based payments are measured at their estimated fair value on the date of grant. Stock-based awards to non-employees are re-measured at fair value each financial reporting date until performance is completed. Stock-based compensation expense recognized during a period is based on the estimated number of awards that are ultimately expected to vest. For stock options and restricted stock that do not vest immediately but which contain only a service vesting feature, we recognize compensation cost on the unvested shares and options on a straight-line basis over the remaining vesting period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of options and the market price of our common stock on the date of grant for the fair value of restricted stock issued. Our determination of fair value of stock-based awards is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and certain other market variables such as the risk-free interest rate.
Comprehensive Loss	Comprehensive Loss Comprehensive income (loss) includes all changes in equity during a period except those that resulted from investments by, or distributions to, the Company’s stockholders. Other comprehensive income (loss) refers to revenues, expenses, gains and losses that are included in comprehensive income (loss), but excluded from net loss as these amounts are recorded directly as an adjustment to stockholders’ equity. The Company had no items of other comprehensive income (loss) for the three and nine months ended September 30, 2015 and 2014. Accordingly, the Company's comprehensive loss and net loss are the same for all periods presented.
Segment Information	Segment Information Accounting Standards Codification (“ASC”) 280, Disclosures about Segments of an Enterprise and Related Information
Fair Value Measurement	Fair Value Measurement Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby observable and unobservable inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchy levels of inputs to measure fair value: Level 1 Inputs that utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 Inputs that utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active. Level 3: Inputs that utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity. A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement. At September 30, 2015 and December 31, 2014, the Company’s financial instruments consist primarily of cash, accounts receivable, accounts payable and accrued expenses. Due to their short-term nature, the carrying amounts of the Company’s financial instruments approximated their fair values.
Basic and Diluted Earnings (Loss) Per Share	Basic and Diluted Earnings (Loss) Per Share Basic net loss per share is computed by dividing net loss available to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potential dilutive securities outstanding had been issued. The Company uses the “treasury stock” method to determine the dilutive effect of common stock equivalents such as options, warrants and restricted stock. For the three and nine months ended September 30, 2015 and 2014, the Company incurred a net loss. Accordingly, the Company’s common stock equivalents were anti-dilutive and excluded from the diluted net loss per share computation. The aggregate number of potentially dilutive common stock equivalents outstanding at September 30, 2015 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 1,410,673, which includes up to 193,865 Make-Whole Shares (See NOTE 9 – Warrants), warrants to purchase an aggregate 761,878 shares of common stock, options to purchase an aggregate of 443,480 shares of common stock and unvested restricted stock awards of 11,450 shares of common stock. The aggregate number of potentially dilutive common stock equivalents outstanding at September 30, 2014 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 866,102, which includes warrants to purchase an aggregate 473,522 shares of common stock, options to purchase an aggregate of 369,880 shares of common stock and unvested restricted stock awards of 22,700 shares of common stock.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method in accordance with ASC 740, “Accounting for Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance to the extent that the recoverability of the asset is unlikely to be recognized. The Company follows ASC 740 rules governing uncertain tax positions, which provides guidance for recognition and measurement. This prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. It also provides accounting guidance on recognition, classification and disclosure of these uncertain tax positions. The Company has no uncertain income tax positions. Interest costs and penalties related to income taxes are classified as interest expense and operating expenses, respectively, in the Company's financial statements. For the three and nine months ended September 30, 2015 and 2014, the Company did not recognize any interest or penalty expense related to income taxes. The Company files income tax returns in the U.S. federal jurisdiction and states in which it does business.
Immaterial Correction of Prior Period Presentation	Immaterial Correction of Prior Period Presentation Revised loss per share for the three and six month period ended June 30, 2015 was as follows: (In thousand $) Three Months Ended Six Months Ended June 30, June 30, Net loss attributable to common shareholders, as reported $ (957 ) $ (2,486 ) Less: deemed dividend resulting from warrant modification (225 ) (225 ) Net loss attributable to common shareholders, as revised $ (1,182 ) $ (2,711 ) Net loss per share attributable to common shareholders: Basic and diluted, as reported $ (0.30 ) $ (0.79 ) Basic and diluted, as revised $ (0.37 ) $ (0.87 ) Weighted average number of common shares outstanding: Basic and diluted 3,182 3,133

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2015
Concentration Risk [Line Items]
Summary of Intangible Assets	(In thousand $) September 30, December 31, 2015 2014 Intangibles with finite lives: Intellectual property $ 2,101 $ 2,101 Less: accumulated amortization (312 ) (155 ) Total intangibles with finite lives: 1,789 1,946 Intangibles with indefinite lives: Intellectual property - - Patent costs 44 44 Total intangibles with indefinite lives: 44 44 Total intangible assets, net $ 1,833 $ 1,990
Schedule of revised loss per share	(In thousand $) Three Months Ended Six Months Ended June 30, June 30, Net loss attributable to common shareholders, as reported $ (957 ) $ (2,486 ) Less: deemed dividend resulting from warrant modification (225 ) (225 ) Net loss attributable to common shareholders, as revised $ (1,182 ) $ (2,711 ) Net loss per share attributable to common shareholders: Basic and diluted, as reported $ (0.30 ) $ (0.79 ) Basic and diluted, as revised $ (0.37 ) $ (0.87 ) Weighted average number of common shares outstanding: Basic and diluted 3,182 3,133
Accounts receivable [Member]
Concentration Risk [Line Items]
Schedule of concentrations of net accounts receivable with customers	(In thousand $) September 30, December 31, 2015 2014 Cenegenics $ 700 $ 1,372 Other 12 - Subtotal 712 1,372 Allowance for doubtful accounts (97 ) (390 ) Accounts receivable, net $ 615 $ 982

Inventories, Net (Tables)

Inventories, Net (Tables)	9 Months Ended
	Sep. 30, 2015
Inventories, Net [Abstract]
Summary of Inventory	(In thousand $) September 30, December 31, 2015 2014 Raw materials $ 2,008 $ 1,638 Work in process 1 2 Finished goods 187 443 2,196 2,083 Less: inventory reserves (382 ) (269 ) Inventories, net $ 1,814 $ 1,814

Fixed Assets (Tables)

Fixed Assets (Tables)	9 Months Ended
	Sep. 30, 2015
Fixed Assets [Abstract]
Schedule of fixed assets	(In thousand $) September 30, December 31, 2015 2014 Furniture, fixtures and equipment $ 116 $ 134 Computers and software 66 21 Leasehold improvements 239 239 Other 7 7 Total fixed assets 428 401 Less: accumulated depreciation and amortization (127 ) (88 ) Net book value of fixed assets $ 301 $ 313

Prepaid Expenses, Other Curre22

Prepaid Expenses, Other Current Assets, Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2015
Prepaid Expenses Other Current Assets Accrued Expenses and Other Current Liabilities [Abstract]
Summary of prepaid expenses and other current assets	(In thousand $) September 30, December 31, 2015 2014 Prepaid insurance $ 56 $ 46 Prepaid research and development - 15 Prepaid consulting - 8 Prepaid inventory purchases 250 664 Deferred charges (1) 153 - Other 12 12 Total prepaid expenses and other current assets $ 471 $ 745 (1) Deferred charges represents the cost of inventory shipped to a customer in May 2015. The shipment was related to a settlement agreement with the customer under which there were extended payment terms. Accordingly the Company has deferred the charges until payment of the commensurate sale is received from the customer and revenue is recognized.
Summary of accrued expenses and other current liabilities	(In thousand $) September 30, December 31, 2015 2014 Advertising and promotional expense payable $ 171 $ 171 Audit fees payable 60 25 Deferred rent 50 30 Deferred revenue (1) 228 - Research and development - 49 Accrued salaries and bonuses 38 92 Consulting fees payable 15 96 Other accrued expenses 12 32 Total accrued expenses and other current liabilities $ 574 $ 495 (1) Deferred revenue represents additional revenue to be recognized in connection with inventory shipped to a customer in May 2015. The shipment was related to a settlement agreement with the customer under which there were extended payment terms. Accordingly the Company has deferred the revenue until the related receivable is collected from the customer.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity [Abstract]
Schedule of changes in stockholders equity	(In thousand $) Additional Total Common Stock paid-in Accumulated stockholders' Shares Amount capital deficit equity Balance at December 31, 2014 3,103,300 $ 3 $ 25,100 $ (18,367 ) $ 6,736 Shares issued for services, net (1) 24,000 - 101 - 101 Stock-based compensation expense - - 629 - 629 Exercise of Series D Warrants, net 190,609 - 916 - 916 Net loss - - - (3,780 ) (3,780 ) Balance at September 30, 2015 3,317,909 $ 3 $ 26,746 $ (22,147 ) $ 4,602 (1) Represents 25,000 shares of fully vested restricted common stock issued to a consultant for services, partially offset by the forfeiture of 1,000 shares of restricted common stock previously issued to another consultant.
Schedule of periodical gross proceeds from private placements	(In thousand $) Gross Date Shares Proceeds February 25, 2011 95,334 $ 1,430 May 31, 2011 28,200 423 June 27, 2011 37,500 563 July 12, 2011 1,667 25 December 2, 2011 4,000 40 February 10, 2012 65,000 325 February 14, 2012 80,000 400 March 7, 2012 20,000 100 March 15, 2012 35,000 175 March 22, 2012 5,000 25 April 9, 2012 20,000 100 April 24, 2012 * 4,000 - June 28, 2012 48,000 600 July 6, 2012 411,600 5,145 January 27, 2014 631,346 4,735 November 19, 2014 193,865 1,816 May 18, 2015 190,609 1,001 1,871,121 $ 16,903

Warrants (Tables)

Warrants (Tables) - Warrants [Member]	9 Months Ended
	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of fair value of warrants	Expected volatility 96%-227 % Risk-free interest rate 0.02%-1.87 % Expected term in years 0.0-7.0 Expected dividend yield 0 %
Summary of warrants issued to private placement	Description Grant Date Number of Shares Underlying Warrants Originally Granted Shares Underlying Warrants Exchanged, Exercised or Expired Shares Underlying Warrants Outstanding and Exercisable at September 30, Exercise Price Expiration Term in Years Series A (1) January 27, 2014 315,676 - 315,676 $ 15.00 1.33 Series B (1) January 27, 2014 157,846 - 157,846 $ 45.00 3.32 Series C (2) November 19, 2014 145,399 (142,957 ) 2,442 $ 12.00 4.63 142,957 142,957 $ 9.00 4.63 Series D (2) November 19, 2014 193,865 (193,865 ) - N/A N/A Series E (2) November 19, 2014 145,399 (145,399 ) - N/A N/A 142,957 142,957 $ 9.00 6.63 958,185 (196,307 ) 761,878

Stock Compensation (Tables)

Stock Compensation (Tables)	9 Months Ended
	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of restricted stock award activities	Weighted Average Grant Date Shares Share Price Restricted stock awards unvested at December 31, 2014 22,200 $ 14.95 Granted 25,000 4.04 Vested (34,750 ) 7.77 Forfeited (1,000 ) 7.50 Restricted stock awards unvested at September 30, 2015 11,450 $ 13.55
Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of stock option activities	Weighted Weighted Average Shares Average Remaining Under Exercise Contractual Options Price Term (Years) Balance at December 31, 2014 367,080 $ 14.68 8.50 Options granted 108,000 12.50 Options exercised - - Options cancelled/expired/forfeited (31,600 ) (11.92 ) Balance at September 30, 2015 443,480 $ 14.43 8.09
Summary of assumptions used to value stock options granted using a Black-Scholes model	Expected volatility 98 % Risk-free interest rate 1.39%-1.69 % Expected term in years 5.8-6.3 Expected dividend yield 0 %
Summary of option outstanding and exercisable	Options Outstanding Options Exercisable Weighted Average Weighted Average Range of Remaining Range of Remaining Exercise Options Contractual Exercise Options Contractual $ 7.00 5,000 6.64 $ 7.00 5,000 6.64 $ 8.60 28,500 8.45 $ 8.60 21,875 8.45 $ 10.00 5,120 7.36 $ 10.00 5,120 7.36 $ 11.00 3,000 7.28 $ 11.00 3,000 7.28 $ 12.10 30,500 8.61 $ 12.10 15,250 8.61 $ 12.50 188,800 8.51 $ 12.50 92,800 7.73 $ 12.55 20,000 8.64 $ 12.55 5,000 8.64 $ 13.00 14,600 8.78 $ 13.00 7,300 8.78 $ 13.45 2,000 8.73 $ 13.45 500 8.73 $ 13.50 14,960 8.74 $ 13.50 3,740 8.74 $ 13.75 6,000 8.93 $ 13.75 3,000 8.93 $ 17.50 100,000 7.36 $ 17.50 100,000 7.36 $ 22.50 5,000 5.87 $ 22.50 5,000 5.87 $ 32.00 15,000 5.78 $ 32.00 15,000 5.78 $ 34.50 5,000 5.81 $ 34.50 5,000 5.81 443,480 287,585
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of stock-based compensation	(In thousand $) Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Cost of sales $ - $ - $ - $ - Research & development 25 36 75 100 Selling, general and administrative 140 466 655 1,127 Total stock-based compensation $ 165 $ 502 $ 730 $ 1,227

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies [Abstract]
Summary of future minimum lease payments under the non-cancelable operating lease	(In thousand $) Years Ended December 31, Amount 2015 (remaining three months) $ 45 2016 152 2017 181 2018 187 2019 191 Total $ 756

Nature of Operations, Basis o27

Nature of Operations, Basis of Presentation and Liquidity (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		102 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Nature of Operations and Basis of Presentation (Textual)
Revenue	$ 36	$ 107	$ 124	$ 3,332	$ 7,800
Sale of product	396	232	432	1,282
Direct sales	36	7	57	17
Distributer sales	0	100	67	3,315
Cash to meet current obligations	785	638	785	638	785	$ 1,567	$ 451
Working Capital	2,582		2,582		2,582
Current assets	3,685		3,685		3,685	5,108
Current liabilities	1,103		1,103		1,103	574
Net loss	(1,294)	$ (2,177)	(3,780)	(3,599)
Net cash used in operating activities			(1,971)	(4,667)
Accumulated deficit	(22,147)		(22,147)		(22,147)	$ (18,367)
Net cash provided by financing activities			1,216	$ 4,883	16,561
Term note	$ 300		300		$ 300
Maximum Human Performance (MHP) [Member]
Nature of Operations and Basis of Presentation (Textual)
Sale of product			$ 57
Cenegenics [Member]
Nature of Operations and Basis of Presentation (Textual)
Settlement Agreement, Terms			On November 28, 2014, we entered into a settlement agreement with Cenegenics. Pursuant to the terms of the settlement agreement, we agreed to withdraw our October 10, 2014 request for arbitration before the International Chamber of Commerce and Cenegenics agreed to pay the Company $1,900 by April 2016, including an aggregate of $300 during the fourth quarter of 2014, and $100 per month from January 2015 through April 2016. As of the date of this Form 10-Q, Cenegenics has made all scheduled payments under the terms of the settlement agreement.

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Summary of concentrations of net accounts receivable with customers
Subtotal	$ 712	$ 1,372
Allowance for doubtful accounts	(97)	(390)
Accounts receivable, net	615	982
Cenegenics [Member]
Summary of concentrations of net accounts receivable with customers
Subtotal	700	$ 1,372
Other [Member]
Summary of concentrations of net accounts receivable with customers
Subtotal	$ 12

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Details 1) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Intangibles with finite lives:
Intellectual property	$ 2,101	$ 2,101
Less: accumulated amortization	(312)	(155)
Total intangibles with finite lives:	1,789	1,946
Intangibles with indefinite lives:
Total intangibles with indefinite lives:	44	44
Total intangible assets, net	$ 1,833	$ 1,990
Intellectual Property [Member]
Intangibles with indefinite lives:
Total intangibles with indefinite lives:
Patents [Member]
Intangibles with indefinite lives:
Total intangibles with indefinite lives:	$ 44	$ 44

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Details 2) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2014	Jun. 30, 2015	Sep. 30, 2015	Sep. 30, 2014
Schedule of revised loss per share
Net loss attributable to common shareholders	$ (1,294)	$ (1,182)	$ (2,177)	$ (2,711)	$ (4,005)	$ (3,599)
Net loss per share attributable to common shareholders:
Basic and diluted	$ (0.39)	$ (0.37)	$ (0.75)	$ (0.87)	$ (1.25)	$ (1.28)
Weighted average number of common shares outstanding:
Basic and diluted	3,306	3,182	2,886	3,133	3,192	2,812
As reported [Member]
Schedule of revised loss per share
Net loss attributable to common shareholders		$ (957)		$ (2,486)
Net loss per share attributable to common shareholders:
Basic and diluted		$ (0.30)		$ (0.79)
Deemed dividend resulting from warrant modification [Member]
Schedule of revised loss per share
Net loss attributable to common shareholders		$ (225)		$ (225)

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2011
Summary of Significant Accounting Policies (Textual)
Cash		$ 785		$ 785		$ 1,567
Cash equivalents
Bad debt expense		$ (98)	$ 390	$ (293)	$ 390
Allowance for doubtful accounts		97		$ 97		$ 390
Estimated useful lives of fixed assets				3 to 7 years.
Noncash impairment charges of intangible assets
Intellectual property asset, fair value							$ 2,000
Intangible asset acquired	$ 101
Discount Rate	10.00%
Amortization expense for intangible assets year one		210		$ 210
Amortization expense for intangible assets, year two		210		210
Amortization expense for intangible assets, year three		210		210
Amortization expense for intangible assets, year four		210		210
Amortization expense for intangible assets, year five		210		210
Shipping and handling costs		4	$ 0	$ 8	$ 10
Anti-dilutive excluded from diluted net loss per share computation				1,410,673	866,102
Amortization expense for intangible assets		$ 53		$ 53
Asset impairment charges					$ 5
Patents [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful life of intangible assets				20 years
Intellectual Property [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful life of intangible assets				10 years
Unvested restricted stock awards [Member]
Summary of Significant Accounting Policies (Textual)
Anti-dilutive excluded from diluted net loss per share computation				11,450	22,700
Options Held [Member]
Summary of Significant Accounting Policies (Textual)
Anti-dilutive excluded from diluted net loss per share computation				443,480	369,880
Warrant [Member]
Summary of Significant Accounting Policies (Textual)
Anti-dilutive excluded from diluted net loss per share computation				761,878	473,522
Make-Whole Shares, Warrants [Member]
Summary of Significant Accounting Policies (Textual)
Anti-dilutive excluded from diluted net loss per share computation				193,865

Inventories, Net (Details)

Inventories, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Summary of Inventory
Raw materials	$ 2,008	$ 1,638
Work in process	1	2
Finished goods	187	443
Inventories, gross	2,196	2,083
Less: inventory reserves	(382)	(269)
Inventories, net	$ 1,814	$ 1,814

Fixed Assets (Details)

Fixed Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment, Gross
Total fixed assets	$ 428	$ 401
Less: accumulated depreciation and amortization	(127)	(88)
Net book value of fixed assets	301	313
Furniture, fixtures and equipment [Member]
Property, Plant and Equipment, Gross
Total fixed assets	116	134
Computers and software [Member]
Property, Plant and Equipment, Gross
Total fixed assets	66	21
Leasehold improvements [Member]
Property, Plant and Equipment, Gross
Total fixed assets	239	239
Other [Member]
Property, Plant and Equipment, Gross
Total fixed assets	$ 7	$ 7

Fixed Assets (Details Textuals)

Fixed Assets (Details Textuals) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Fixed Assets (Textual)
Depreciation and amortization expense	$ 14	$ 13	$ 39	$ 37

Debt (Details)

Debt (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Debt (Textual)
Total outstanding balance	$ 400
Periodic payment	$ 100
Frequency of payments	Each month in four (4) consecutive installments of $100.
Term note per annum interest rate	Term Note bears interest at a per annum interest rate equal to the greater of 3.50%, or prime rate plus 1.25%.
Interest rate	4.50%
Debt aggregate principal amount	$ 300

Prepaid Expenses, Other Curre36

Prepaid Expenses, Other Current Assets, Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands		Sep. 30, 2015	Dec. 31, 2014
Summary of prepaid expenses and other current assets
Prepaid insurance		$ 56	$ 46
Prepaid research and development			15
Prepaid consulting			8
Prepaid inventory purchases		$ 250	$ 664
Deferred charges(1)	[1]	153
Other		12	$ 12
Total prepaid expenses and other current assets		$ 471	$ 745
[1]	Deferred charges represents the cost of inventory shipped to a customer in May 2015. The shipment was related to a settlement agreement with the customer under which there were extended payment terms. Accordingly the Company has deferred the charges until payment of the commensurate sale is received from the customer and revenue is recognized.

Prepaid Expenses, Other Curre37

Prepaid Expenses, Other Current Assets, Accrued Expenses and Other Current Liabilities (Details 1) - USD ($) $ in Thousands		Sep. 30, 2015	Dec. 31, 2014
Summary of accrued liabilities
Advertising and promotional expense payable		$ 171	$ 171
Audit fees payable		60	25
Deferred rent		50	$ 30
Deferred revenue	[1]	$ 228
Research and development			$ 49
Accrued salaries and bonuses		$ 38	92
Consulting fees payable		15	96
Other accrued expenses		12	32
Total accrued expenses and other current liabilities		$ 574	$ 495
[1]	Deferred revenue represents additional revenue to be recognized in connection with inventory shipped to a customer in May 2015. The shipment was related to a settlement agreement with the customer under which there were extended payment terms. Accordingly the Company has deferred the revenue until the related receivable is collected from the customer.

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Class of Stock [Line Items]
Beginning Balance				$ 6,736
Shares issued for services, net(1)	[1]			101
Stock-based compensation expense				629
Exercise of Series D Warrants, net of issuance costs of $85				916
Net loss		$ (1,294)	$ (2,177)	(3,780)	$ (3,599)
Ending Balance		4,602		4,602
Common Stock [Member]
Class of Stock [Line Items]
Beginning Balance				$ 3
Beginning Balance, shares				3,103,300
Shares issued for services, net(1)	[1]
Shares issued for services, net(1), Shares	[1]			24,000
Stock-based compensation expense
Exercise of Series D Warrants, net of issuance costs of $85
Exercise of Series D Warrants, net of issuance costs of $85, Shares				190,609
Net loss
Ending Balance		$ 3		$ 3
Ending Balance, shares		3,317,909		3,317,909
Additional paid-in capital [Member]
Class of Stock [Line Items]
Beginning Balance				$ 25,100
Shares issued for services, net(1)	[1]			101
Stock-based compensation expense				629
Exercise of Series D Warrants, net of issuance costs of $85				$ 916
Net loss
Ending Balance		$ 26,746		$ 26,746
Accumulated deficit [Member]
Class of Stock [Line Items]
Beginning Balance				(18,367)
Net loss				(3,780)
Ending Balance		$ (22,147)		$ (22,147)
[1]	Represents 25,000 shares of fully vested restricted common stock issued to a consultant for services, partially offset by the forfeiture of 1,000 shares of restricted common stock previously issued to another consultant.

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Class of Stock [Line Items]
Shares	3,317,909		3,103,300
Gross Proceeds		$ 4,735
February 25, 2011 [Member]
Class of Stock [Line Items]
Shares	95,334
Gross Proceeds	$ 1,430
May 31, 2011 [Member]
Class of Stock [Line Items]
Shares	28,200
Gross Proceeds	$ 423
June 27, 2011 [Member]
Class of Stock [Line Items]
Shares	37,500
Gross Proceeds	$ 563
July 12, 2011 [Member]
Class of Stock [Line Items]
Shares	1,667
Gross Proceeds	$ 25
December 2, 2011 [Member]
Class of Stock [Line Items]
Shares	4,000
Gross Proceeds	$ 40
February 10, 2012 [Member]
Class of Stock [Line Items]
Shares	65,000
Gross Proceeds	$ 325
February 14, 2012 [Member]
Class of Stock [Line Items]
Shares	80,000
Gross Proceeds	$ 400
March 7, 2012 [Member]
Class of Stock [Line Items]
Shares	20,000
Gross Proceeds	$ 100
March 15, 2012 [Member]
Class of Stock [Line Items]
Shares	35,000
Gross Proceeds	$ 175
March 22, 2012 [Member]
Class of Stock [Line Items]
Shares	5,000
Gross Proceeds	$ 25
April 9, 2012 [Member]
Class of Stock [Line Items]
Shares	20,000
Gross Proceeds	$ 100
April 24, 2012 [Member]
Class of Stock [Line Items]
Shares	4,000
Gross Proceeds
June 28, 2012 [Member]
Class of Stock [Line Items]
Shares	48,000
Gross Proceeds	$ 600
July 6, 2012 [Member]
Class of Stock [Line Items]
Shares	411,600
Gross Proceeds	$ 5,145
January 27, 2014 [Member]
Class of Stock [Line Items]
Shares	631,346
Gross Proceeds	$ 4,735
November 19, 2014 [Member]
Class of Stock [Line Items]
Shares	193,865
Gross Proceeds	$ 1,816
May 18, 2015 [Member]
Class of Stock [Line Items]
Shares	190,609
Gross Proceeds	$ 1,001

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Stockholders' Equity (Textual)
Proceeds from private placement of common stock		$ 4,735
Restricted common stock issued, Shares	25,000
Shares of restricted common stock, forfeiture	1,000
Net of issuance costs	$ 85

Warrants (Details)

Warrants (Details) - Warrants [Member]	9 Months Ended
	Sep. 30, 2015
Assumptions used to calculate the incremental fair value of the warrants
Expected dividend yield	0.00%
Minimum [Member]
Assumptions used to calculate the incremental fair value of the warrants
Expected volatility	96.00%
Risk-free interest rate	0.02%
Expected term in years	0 years
Maximum [Member]
Assumptions used to calculate the incremental fair value of the warrants
Expected volatility	227.00%
Risk-free interest rate	1.87%
Expected term in years	7 years

Warrants (Details 1)

Warrants (Details 1) - $ / shares		May. 18, 2015	Sep. 30, 2015
Summary of warrants issued to private placement stockholders and consultants
Shares Underlying Warrants Outstanding and Exercisable at September 30, 2015			761,878
Warrants [Member]
Summary of warrants issued to private placement stockholders and consultants
Number of Shares Underlying Warrants Originally Granted			958,185
Shares Underlying Warrants Exchanged, Exercised Exercised or Expired			(196,307)
Series A Warrants [Member]
Summary of warrants issued to private placement stockholders and consultants
Grant Date	[1]		Jan. 27, 2014
Number of Shares Underlying Warrants Originally Granted	[1]		315,676
Shares Underlying Warrants Exchanged, Exercised Exercised or Expired	[1]
Shares Underlying Warrants Outstanding and Exercisable at September 30, 2015	[1]		315,676
Exercise Price	[1]		$ 15
Expiration Term in Years	[1]		1 year 3 months 29 days
Series B Warrants [Member]
Summary of warrants issued to private placement stockholders and consultants
Grant Date	[1]		Jan. 27, 2014
Number of Shares Underlying Warrants Originally Granted	[1]		157,846
Shares Underlying Warrants Exchanged, Exercised Exercised or Expired	[1]
Shares Underlying Warrants Outstanding and Exercisable at September 30, 2015	[1]		157,846
Exercise Price	[1]		$ 45
Expiration Term in Years	[1]		3 years 3 months 26 days
Series C Warrants [Member]
Summary of warrants issued to private placement stockholders and consultants
Grant Date	[2]		Nov. 19, 2014
Number of Shares Underlying Warrants Originally Granted	[2]		145,399
Series C Warrants [Member] | Minimum [Member]
Summary of warrants issued to private placement stockholders and consultants
Shares Underlying Warrants Exchanged, Exercised Exercised or Expired	[2]		(142,957)
Shares Underlying Warrants Outstanding and Exercisable at September 30, 2015	[2]		2,442
Exercise Price		$ 9	$ 12	[2]
Expiration Term in Years	[2]		4 years 7 months 17 days
Series C Warrants [Member] | Maximum [Member]
Summary of warrants issued to private placement stockholders and consultants
Shares Underlying Warrants Exchanged, Exercised Exercised or Expired	[2]		142,957
Shares Underlying Warrants Outstanding and Exercisable at September 30, 2015	[2]		142,957
Exercise Price		12	$ 9	[2]
Expiration Term in Years	[2]		4 years 7 months 17 days
Series D Warrants [Member]
Summary of warrants issued to private placement stockholders and consultants
Grant Date	[2]		Nov. 19, 2014
Number of Shares Underlying Warrants Originally Granted	[2]		193,865
Shares Underlying Warrants Exchanged, Exercised Exercised or Expired			(193,865)
Shares Underlying Warrants Outstanding and Exercisable at September 30, 2015	[2]
Exercise Price		5.25
Series D Warrants [Member] | Minimum [Member]
Summary of warrants issued to private placement stockholders and consultants
Exercise Price		5.25
Series D Warrants [Member] | Maximum [Member]
Summary of warrants issued to private placement stockholders and consultants
Exercise Price		9.37
Series E Warrants [Member]
Summary of warrants issued to private placement stockholders and consultants
Grant Date	[2]		Nov. 19, 2014
Number of Shares Underlying Warrants Originally Granted	[2]		145,399
Series E Warrants [Member] | Minimum [Member]
Summary of warrants issued to private placement stockholders and consultants
Shares Underlying Warrants Exchanged, Exercised Exercised or Expired	[2]		(145,399)
Shares Underlying Warrants Outstanding and Exercisable at September 30, 2015	[2]
Exercise Price		9	$ 15	[2]
Series E Warrants [Member] | Maximum [Member]
Summary of warrants issued to private placement stockholders and consultants
Shares Underlying Warrants Exchanged, Exercised Exercised or Expired	[2]		142,957
Shares Underlying Warrants Outstanding and Exercisable at September 30, 2015	[2]		142,957
Exercise Price		$ 15	$ 9	[2]
Expiration Term in Years	[2]		6 years 7 months 17 days
[1]	Issued in connection with the January 27, 2014 private placement transaction.
[2]	Issued in connection with the November 19, 2014 registered-direct public offering, and subsequently revised pursuant to Warrant Exercise Agreements entered into on May 18, 2015.

Warrants (Details Textual)

Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		May. 18, 2015	Nov. 19, 2014	Jan. 27, 2014	Sep. 30, 2015		Sep. 30, 2014
Warrants (Textual)
Net of cash fees					$ 916
Change in fair value of warrants					$ 225
Estimated fair value of warrants			$ 1,049
Market price of common stock					$ 2.68
Series D Warrants [Member]
Warrants (Textual)
Number of Shares Underlying Warrants Originally Granted	[1]				193,865
Number of warrants issued to purchase common stock		190,609
Exercise Price		$ 5.25
Unexercised warrants		3,256
Change in fair value of warrants		$ 136
Estimated fair value of warrants		0
Series C Warrants [Member]
Warrants (Textual)
Number of Shares Underlying Warrants Originally Granted	[1]				145,399
Change in fair value of warrants		38
Estimated fair value of warrants		$ 569
Series E Warrants [Member]
Warrants (Textual)
Number of Shares Underlying Warrants Originally Granted	[1]				145,399
Unexercised warrants		2,442
Change in fair value of warrants		$ 51
Estimated fair value of warrants		$ 653
Public Offering [Member]
Warrants (Textual)
Number of Shares Underlying Warrants Originally Granted			484,663
Common stock price, per share			$ 14.06
Additional share issued			193,865
Minimum [Member] | Series D Warrants [Member]
Warrants (Textual)
Exercise Price		$ 5.25
Minimum [Member] | Series C Warrants [Member]
Warrants (Textual)
Exercise Price		9			$ 12	[1]
Minimum [Member] | Series E Warrants [Member]
Warrants (Textual)
Exercise Price		9			15	[1]
Maximum [Member] | Series D Warrants [Member]
Warrants (Textual)
Exercise Price		9.37
Maximum [Member] | Series C Warrants [Member]
Warrants (Textual)
Exercise Price		12			9	[1]
Maximum [Member] | Series E Warrants [Member]
Warrants (Textual)
Exercise Price		$ 15			$ 9	[1]
Warrant [Member]
Warrants (Textual)
Number of Shares Underlying Warrants Originally Granted					958,185
Aggregate proceeds from issuance of warrants		$ 1,001
Cash fees		85
Change in fair value of warrants		$ 225
Warrant [Member] | Series A January 27, 2014
Warrants (Textual)
Number of Shares Underlying Warrants Originally Granted					315,676
Exercise Price					$ 15
Expected Term					3 years
Warrant [Member] | Series B January 27, 2014
Warrants (Textual)
Number of Shares Underlying Warrants Originally Granted					157,846
Exercise Price					$ 45
Expected Term					5 years
Warrant [Member] | Series C November 19, 2014
Warrants (Textual)
Number of Shares Underlying Warrants Originally Granted					145,399
Exercise Price					$ 12
Estimated fair value of warrants					$ 969
Expected Term					5 years 6 months
Warrants holders entitle to purchase shares of common stock period, Description					66-months
Warrant [Member] | Series D November 19, 2014
Warrants (Textual)
Number of Shares Underlying Warrants Originally Granted					193,865
Exercise Price					$ 9.37
Estimated fair value of warrants					$ 470
Expected Term					6 months
Warrants holders entitle to purchase shares of common stock period, Description					6-months
Warrant [Member] | Series E November 19, 2014
Warrants (Textual)
Number of Shares Underlying Warrants Originally Granted					145,399
Exercise Price					$ 15
Estimated fair value of warrants					$ 1,048
Warrants holders entitle to purchase shares of common stock period, Description					90-months
Warrant [Member] | Private Placement [Member]
Warrants (Textual)
Number of Shares Underlying Warrants Originally Granted				473,522
Estimated fair value of warrants				$ 2,486
[1]	Issued in connection with the November 19, 2014 registered-direct public offering, and subsequently revised pursuant to Warrant Exercise Agreements entered into on May 18, 2015.

Stock Compensation (Details)

Stock Compensation (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Ending Balance, Shares Underlying Options	443,480
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning Balance, Shares Under Options	367,080
Options granted, Shares Under Options	108,000
Options exercised, Shares Under Options
Options cancelled/expired/forfeited, Shares Under Options	(31,600)
Ending Balance, Shares Underlying Options	443,480	367,080
Beginning Balance, Weighted Average Exercise Price	$ 14.68
Options granted, Weighted Average Exercise Price	$ 12.50
Options exercised, Weighted Average Exercise Price
Options cancelled/expired/forfeited, Weighted Average Exercise Price	$ (11.92)
Ending Balance, Weighted Average Exercise Price	$ 14.43	$ 14.68
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	8 years 1 month 2 days	8 years 6 months

Stock Compensation (Details 1)

Stock Compensation (Details 1) - Stock Options [Member]	9 Months Ended
	Sep. 30, 2015
Assumption used to value options using Black-scholes model
Expected volatility	98.00%
Expected dividend yield	0.00%
Maximum [Member]
Assumption used to value options using Black-scholes model
Risk-free interest rate	1.69%
Expected term (years)	6 years 3 months 18 days
Minimum [Member]
Assumption used to value options using Black-scholes model
Risk-free interest rate	1.39%
Expected term (years)	5 years 9 months 18 days

Stock Compensation (Details 2)

Stock Compensation (Details 2)	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Summary of option outstanding and exercisable
Options outstanding	443,480
Options Exercisable	287,585
$ 7.00 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price | $ / shares	$ 7
Options outstanding	5,000
Options Outstanding, Weighted Average Remaining Contractual Life	6 years 7 months 21 days
Options Exercisable, Range of Exercise Price | $ / shares	$ 7
Options Exercisable	5,000
Options Exercisable, Weighted Average Remaining Contractual Life	6 years 7 months 21 days
$ 8.60 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price | $ / shares	$ 8.60
Options outstanding	28,500
Options Outstanding, Weighted Average Remaining Contractual Life	8 years 5 months 12 days
Options Exercisable, Range of Exercise Price | $ / shares	$ 8.60
Options Exercisable	21,875
Options Exercisable, Weighted Average Remaining Contractual Life	8 years 5 months 12 days
$ 10.00 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price | $ / shares	$ 10
Options outstanding	5,120
Options Outstanding, Weighted Average Remaining Contractual Life	7 years 4 months 10 days
Options Exercisable, Range of Exercise Price | $ / shares	$ 10
Options Exercisable	5,120
Options Exercisable, Weighted Average Remaining Contractual Life	7 years 4 months 10 days
$ 11.00 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price | $ / shares	$ 11
Options outstanding	3,000
Options Outstanding, Weighted Average Remaining Contractual Life	7 years 3 months 11 days
Options Exercisable, Range of Exercise Price | $ / shares	$ 11
Options Exercisable	3,000
Options Exercisable, Weighted Average Remaining Contractual Life	7 years 3 months 11 days
$ 12.10 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price | $ / shares	$ 12.10
Options outstanding	30,500
Options Outstanding, Weighted Average Remaining Contractual Life	8 years 7 months 10 days
Options Exercisable, Range of Exercise Price | $ / shares	$ 12.10
Options Exercisable	15,250
Options Exercisable, Weighted Average Remaining Contractual Life	8 years 7 months 10 days
$ 12.50 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price | $ / shares	$ 12.50
Options outstanding	188,800
Options Outstanding, Weighted Average Remaining Contractual Life	8 years 6 months 4 days
Options Exercisable, Range of Exercise Price | $ / shares	$ 12.50
Options Exercisable	92,800
Options Exercisable, Weighted Average Remaining Contractual Life	7 years 8 months 23 days
$ 12.55 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price | $ / shares	$ 12.55
Options outstanding	20,000
Options Outstanding, Weighted Average Remaining Contractual Life	8 years 7 months 21 days
Options Exercisable, Range of Exercise Price | $ / shares	$ 12.55
Options Exercisable	5,000
Options Exercisable, Weighted Average Remaining Contractual Life	8 years 7 months 21 days
$ 13.00 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price | $ / shares	$ 13
Options outstanding	14,600
Options Outstanding, Weighted Average Remaining Contractual Life	8 years 9 months 11 days
Options Exercisable, Range of Exercise Price | $ / shares	$ 13
Options Exercisable	7,300
Options Exercisable, Weighted Average Remaining Contractual Life	8 years 9 months 11 days
$ 13.45 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price | $ / shares	$ 13.45
Options outstanding	2,000
Options Outstanding, Weighted Average Remaining Contractual Life	8 years 8 months 23 days
Options Exercisable, Range of Exercise Price | $ / shares	$ 13.45
Options Exercisable	500
Options Exercisable, Weighted Average Remaining Contractual Life	8 years 8 months 23 days
$ 13.50 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price | $ / shares	$ 13.50
Options outstanding	14,960
Options Outstanding, Weighted Average Remaining Contractual Life	8 years 8 months 27 days
Options Exercisable, Range of Exercise Price | $ / shares	$ 13.50
Options Exercisable	3,740
Options Exercisable, Weighted Average Remaining Contractual Life	8 years 8 months 27 days
$ 13.75 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price | $ / shares	$ 13.75
Options outstanding	6,000
Options Outstanding, Weighted Average Remaining Contractual Life	8 years 11 months 5 days
Options Exercisable, Range of Exercise Price | $ / shares	$ 13.75
Options Exercisable	3,000
Options Exercisable, Weighted Average Remaining Contractual Life	8 years 11 months 5 days
$ 17.50 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price | $ / shares	$ 17.50
Options outstanding	100,000
Options Outstanding, Weighted Average Remaining Contractual Life	7 years 4 months 10 days
Options Exercisable, Range of Exercise Price | $ / shares	$ 17.50
Options Exercisable	100,000
Options Exercisable, Weighted Average Remaining Contractual Life	7 years 4 months 10 days
$ 22.50 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price | $ / shares	$ 22.50
Options outstanding	5,000
Options Outstanding, Weighted Average Remaining Contractual Life	5 years 10 months 13 days
Options Exercisable, Range of Exercise Price | $ / shares	$ 22.50
Options Exercisable	5,000
Options Exercisable, Weighted Average Remaining Contractual Life	5 years 10 months 13 days
$ 32.00 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price | $ / shares	$ 32
Options outstanding	15,000
Options Outstanding, Weighted Average Remaining Contractual Life	5 years 9 months 11 days
Options Exercisable, Range of Exercise Price | $ / shares	$ 32
Options Exercisable	15,000
Options Exercisable, Weighted Average Remaining Contractual Life	5 years 9 months 11 days
$ 34.50 [Member]
Summary of option outstanding and exercisable
Options Outstanding, Range of Exercise Price | $ / shares	$ 34.50
Options outstanding	5,000
Options Outstanding, Weighted Average Remaining Contractual Life	5 years 9 months 22 days
Options Exercisable, Range of Exercise Price | $ / shares	$ 34.50
Options Exercisable	5,000
Options Exercisable, Weighted Average Remaining Contractual Life	5 years 9 months 22 days

Stock Compensation (Details 3)

Stock Compensation (Details 3) - Restricted Stock Issuances [Member]	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Shares	22,200
Shares granted, Shares	25,000
Shares vested, Shares	(34,750)
Shares forfeited, Shares	(1,000)
Ending Balance, Shares	11,450
Beginning Balance, Weighted Average Grant Date Share Price | $ / shares	$ 14.95
Shares granted, Weighted Average Grant Date Share Price | $ / shares	4.04
Shares vested, Weighted Average Grant Date Share Price | $ / shares	7.77
Shares forfeited, Weighted Average Grant Date Share Price | $ / shares	7.50
Ending Balance, Weighted Average Grant Date Share Price | $ / shares	$ 13.55

Stock Compensation (Details 4)

Stock Compensation (Details 4) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 165	$ 502	$ 730	$ 1,227
Cost of sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation
Research & development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 25	$ 36	$ 75	$ 100
Selling, general and administrative expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 140	$ 466	$ 655	$ 1,127

Stock Compensation (Details Tex

Stock Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Options outstanding	443,480		443,480
Weighted average grant date fair value	$ 5.22		$ 5.22
Market price of common stock	$ 2.68		$ 2.68
Share-based Compensation	$ 165	$ 502	$ 730	$ 1,227
2012 Equity Incentive Plan [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Number of shares authorized for issuance	550,000		550,000
Common stock reserved for issuance	136,520		136,520
Options outstanding	30,000		30,000
Vested options, Weighted average remaining contractual life			7 years 7 months 6 days
Vested options Weighted average exercise price, per share	$ 15.38		$ 15.38
Weighted average unvested restricted stock remaining term			1 year 6 months
Aggregate unrecognized compensation expense of options	$ 1,018		$ 1,018
2012 Equity Incentive Plan [Member] | Minimum [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Vesting terms range			1 month 6 days
2012 Equity Incentive Plan [Member] | Maximum [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Vesting terms range			3 years 3 months 18 days
Stock Options [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Options outstanding	443,480		443,480		367,080
Aggregate intrinsic value of outstanding options	$ 0		$ 0
Aggregate intrinsic value of exercisable options	$ 0		$ 0
Market price of common stock	$ 2.68		$ 2.68
Number of shares non-vested	155,895		155,895

Commitments and Contingencies50

Commitments and Contingencies (Details) $ in Thousands	Sep. 30, 2015USD ($)
Summary of future minimum lease payments under the non-cancelable operating lease
2015 (remaining three months)	$ 45
2,016	152
2,017	181
2,018	187
2,019	191
Total	$ 756

Commitments and Contingencies51

Commitments and Contingencies (Details Textual) € in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015EUR (€)	Dec. 31, 2014USD ($)	Dec. 31, 2014EUR (€)
Commitments and Contingencies (Textual)
Rent expense	$ 61	$ 20	$ 172	$ 56
Prepaid expenses and other current assets	471		$ 471			$ 745
Lease expiration date			Dec. 31, 2019
Percentage of matching contribution of employer			100.00%
Description of matching contribution of defined contribution plan			The Company's matching contribution is equal to 100 percent on the first four percent of a participant's compensation which is deferred as an elective deferral.
Matching contribution, amount	10	$ 9	$ 37	$ 16
Renewal term of agreement			We have two options to renew our lease for an additional three years each.
Term of lease			5 years
Supply Agreement [Member]
Commitments and Contingencies (Textual)
Minimum purchase obligations under the agreement, 2015	2,201		$ 2,201		€ 1,957
Minimum purchase obligations under the agreement, 2016	1,943		1,943		1,728
Minimum purchase obligations under the agreement	1,457		1,457		€ 1,296	$ 258	€ 230
Prepaid expenses and other current assets	$ 250		$ 250
Expiration date of agreement			Dec. 31, 2016
Renewal term of agreement			May be renewed for additional one-year periods unless terminated by either party by giving a ninety day notice before the expiration of the current term.